Cafepharma, Inc on LinkedIn: #jnj #adc #merck #novartis #jpmhc24 #rnai #pharma #pharmanews #biotech… (2024)

🚀 Exciting News in Biopharmaceutical Innovation! 🌐Hovione, a pioneering leader in the pharmaceutical industry, has just announced its acquisition of ExtremoChem Lda, a cutting-edge start-up focused on revolutionizing biopharmaceuticals through the development of bio-inspired synthetic sugars. 🌱💉ExtremoChem's groundbreaking work involves the creation of proprietary sugars, inspired by molecules found in extremophiles—organisms thriving in the harshest environments. 🦠 These synthetic analogues show tremendous promise in enhancing the stability, reducing viscosity, and improving delivery performance of proteins and other biopharmaceuticals throughout their life cycle.Dr. Jean-Luc Herbeaux, Hovione's CEO, expressed enthusiasm about the acquisition, emphasizing the significance of these synthetic sugars in optimizing formulations. 🧪 This strategic move aligns with Hovione's commitment to providing customers with a unique toolkit to tackle stability challenges encountered during biopharmaceutical development.Filipe Aguiar, ExtremoChem’s Managing Director, shared his delight about the acquisition, highlighting Hovione's track record of industrializing innovative technologies. 🤝 This collaboration promises a faster and broader market adoption of ExtremoChem's groundbreaking science.Hovione's dedication to expanding its technology platforms is evident in this acquisition. 🌐 The company's investments in new assets and innovative technologies reflect a commitment to meeting the growing demand for integrated and differentiated development and manufacturing services in drug substance, particle engineering, and drug product.A fantastic leap forward in the world of pharmaceuticals! 👏🔬 #Hovione #ExtremoChem #BiopharmaceuticalInnovation #PharmaIndustry #ScienceAdvancements #TechnologyAcquisition #DrugDevelopment

2

Today we announce a change to the terms to the Letter of Intent signed with TheoremRx Inc.The exclusivity provided has been restricted geographically and no longer covers the Greater China region. Until further review, exclusivity remains in place for TheoremRx for all other regions.Speaking about the change, ValiRx CEO Dr Suzy Dilly said: "Global exclusivity was initially awarded to TheoremRx to enable the progression of their financing, which on completion will enable execution of the sub-license of VAL201 to TheoremRx. We remain fully supportive of the TheoremRx team and continue to closely monitor their progress. However, this modification to the agreement allows ValiRx to explore additional partners in a defined geographic region while TheoremRx continue their process. Recent evidence suggests that China is increasing investment in innovative pharmaceutical development and may offer additional routes for commercialisation.”Find out more about the change within the Regulatory News section on our website: https://lnkd.in/dc87_Ti#BioTech #CancerResearch #CancerTherapeutics

5

1 Comment

Amazing to witness the aquisition of Extremochem, a science-based startup, created from the work of a PhD Student (Eva Lourenço) at ITQB NOVA from Universidade Nova de Lisboa, being now acquired by one of the big CDMOs in Portugal, Hovione. The sky is the limit for the incredible portfolio of molecules with stabilizing properties that was developed by the incredible team with whom I had the pleasure to collaborate many times. Many congrats (and thanks) to Eva Lourenço, Rita Ventura, Christopher Mayco*ck for your resilience, hard work, creativity and for against all odds in this country (Portugal) that is completely risk-adverse, be able to develop a portfolio of patents and create products that are now market ready. It is a great example for researchers in academia in Portugal. It's definitely possible and we need more and more examples like yours. #extremochem #hovione #startup #aquisition #sciencebased #innovation #chemistry

35

2 Comments

New paper alert 🥳A team from our CCeMMP Monash Institute of Pharmaceutical Sciences node recently solved the #CryoEM Structure of the Human Amylin 1 Receptor in Complex with CGRP and Gs Protein - read more here: https://lnkd.in/gxRRmwGj #GPCR #drugdiscovery #migraine(The structure render was created in Blender using the #MolecularNodes addon by Brady Johnston 👏 )

34

🔬 Excited to share some of our research findings from the Franz Ziel GmbH laboratory!I'm pleased to share our recently published article (EJPPS - European Journal of Parenteral and Pharmaceutical Sciences) exploring the interaction between residual cleaning agents and vH₂O₂ in our research at the Franz Ziel lab. While not groundbreaking, our findings shed light on an important area that requires further investigation.📰 Dive into the details of our study here: https://lnkd.in/eHeXq3qiThis work underscores the need for continued research to elucidate the interaction between cleaning agents and vH₂O₂. Together, we are moving forward refining bio-decontamination practices and ensuring efficacy in such critical processes.🧪#BioDecontamination #ResearchInsights #FranzZiel

38

Check out this free webinar with IPWatchdog presented by my friend Eyal Barash this Thursday, discussing the recent Supreme Court'sAmgen v. Sanofidecision in the context of pharmaceutical solid forms. Eyal will discuss how the case may (or may not) affect how to claim genus crystalline forms directed to, for example, salts, solvates, cocrystals, and polymorphs. https://lnkd.in/gYipkmB9

9

It was great meeting bright minds from Biotech/Pharma at #BiotechTuesday event and discussing Drug Development pathway! The insights received from the leaders in the Industry are always impressive!#drugdevelopment #cmc #preformulation #formulation #manufacturing #drugsubstance #drugproduct #research

14

Spark and Flare can help streamlining the designing PROTACs.Please join this webinar!

10

Runyu Product Show-198Cas No.:213697-53-1MF： C26H36NPAbbreviation: DavePhosFull Name:2-(Dicyclohexylphosphino)-2'-(N,N-dimethylamino)biphenylPurity:98%Runyu mainly focus on four parts:1. Phosphine Ligands;2. Nucleotide reagents;3. Pd- Catslyst;4. Constrained-geometry Catalyst (CGC).Runyu is manufacture with R&D ：---ISO 9001:2008 Certified---100% succeed Onsite/online audit since 2017---One research center + two large-scale production workshops---Supply stable and continuouslyIf interested in, welcome to contact with us: E-mail: yi.ding@runvmat.com #Sphos #drugdiscovery #cro #cdmo #crdmo #CMO #pharmaceutical #pharma #catalyst #lifesciences #biotech #Runyu #API #drugdevelopment #pharmaceuticalindustry #pharmaceutical #pharmaindustry

1

A high percentage of pharmaceutical targets are ‘undruggable’ by small molecules. To address this issue, researchers have recently turned to Proteolysis Targeting Chimeras (PROTACs®).Join our next webinar on 12th December, 'Streamlining the design of PROTACs® and PROTAC linkers', where we'll explore PROTACs and demonstrate how software solutionsSpark™andFlare™can help overcome some of these challenges and streamline the design of PROTACs and PROTAC linkers.Register here: https://lnkd.in/e_AKHZmU #DMTA #CADD #smallmolecule #drugdiscovery #drugdesign #PROTACS

32